|
| Accueil - Information professionnelle sur Cosentyx 150 mg - Changements - 07.03.2019 | |
| 8 Changements de l'information professionelle Cosentyx 150 mg |
-Placebo n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI)- + Placebo n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI)
-Placebo n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) Étanercept n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) Étanercept n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) Étanercept n (%) (95% CI)- + Placebo n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) Étanercept n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) Étanercept n (%) (95% CI) 150 mg n (%) (95% CI) 300 mg n (%) (95% CI) Étanercept n (%) (95% CI)
-Sécukinumab 300 mg Ustékinumab* Sécukinumab 300 mg Ustékinumab*- + Sécukinumab 300 mg Ustékinumab* Sécukinumab 300 mg Ustékinumab*
-Placebo 75 mg 150 mg 300 mg- + Placebo 75 mg 150 mg 300 mg
|
|
|
